RY_SW01 Cell Injection Therapy in Systemic Sclerosis
Status:
Recruiting
Trial end date:
2035-12-31
Target enrollment:
Participant gender:
Summary
Systemic sclerosis (SSc) tends to progress to involve multiple vital organs within 5 years of
diagnosis, significantly impacting patient prognosis and survival. Clinical indications
suggest that early intervention is more favorable for long-term outcomes in patients.
Although guidelines recommend various drugs for symptomatic treatment, there is currently no
standard therapy or effective medication to slow the progression of the disease. Therefore,
for patients with diffuse SSc, as defined by a skin score of 10≤mRSS≤30 points, who have been
treated with at least two therapies, including steroids, immunosuppressive agents, biologics,
etc., within 5 years of diagnosis, the applicant intends to develop a drug that can both
modulate the immune system and counteract fibrosis. The goal is to provide long-term benefits
to patients through early intervention.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jiangsu Renocell Biotech Company
Collaborator:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School